Second-line Anti-Retroviral therapy in Africa: a randomised trial to evaluate the feasibility of maintenance monotherapy with ritonavir-boosted lopinavir (Aluvia® tablets) following initiation with 24 weeks of combination therapy in second-line anti-retroviral therapy in Africa

Not Applicable

Completed

• Conditions: HIV/AIDS; Infections and Infestations

• Registration Number: ISRCTN53817258
• Lead Sponsor: Medical Research Council Clinical Trials Unit (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-05-31
• Last Update Posted: 15 January 2018

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

1. Enrolled in the DART trial (ISRCTN13968779 at http://www.controlled-trials.com/ISRCTN13968779)
2. Failed first-line antiretroviral therapy (clinically/immunologically) and having completed 24 weeks of second-line combination antiretroviral therapy including ritonavir-boosted lopinavir (as either Aluvia® heat-stable tablets or Kaletra® capsules)
3. Documented informed consent
4. Life expectancy of at least 3 months

Exclusion Criteria

Pregnant or breast-feeding

Study & Design

• Study Type: Interventional
• Study Design: Not specified